Person · CIK 1737329

Robert Iannone

EVP at Jazz Pharmaceuticals; director at Pliant Therapeutics and Autolus Therapeutics

Earlier: iTeos Therapeutics, Jounce Therapeutics and Immunomedics

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$22M

Noticed on Form 144$22M

Bought on Form 4$0

Companies6

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Jazz Pharmaceuticals JAZZ	Ordinary Shares	Directly	65,686	Aug 27, 2026 · Filing · EDGAR
Pliant Therapeutics PLRX	Stock Option (Right to Buy) exercise $1.13, expires Jul 9, 2036, into Common Stock	Directly	60,000	Jul 9, 2026 · Filing · EDGAR
Autolus Therapeutics AUTL	Share Option (Right to Buy) exercise $1.61, expires Jun 29, 2036, into American Depositary Shares	Directly	47,500	Jun 29, 2026 · Filing · EDGAR
Autolus Therapeutics AUTL	Restricted Share Units into American Depositary Shares	Directly	31,667	Jun 29, 2026 · Filing · EDGAR
iTeos Therapeutics	Stock Option (Right to Buy) exercise $16.32, expires Jun 11, 2034, into Common Stock	Directly	24,200	Jun 11, 2024 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)
Q3 2026	$19.2M	$19.2M
Q4 2025	$1.2M	$1.2M
Q1 2025	$1.3M	$1.6M
Q4 2022	$279K	Not machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Jazz Pharmaceuticals JAZZ · Morgan Stanley Smith Barney · 10b5-1 plan adopted May 28, 2026 · 1 notice
Aug 27, 2026	76,921 · ~$19.2M	Aug 27, 2026	Sold as noticed Sold 76,921 in 6 sales, Aug 27 to Aug 27 · $19.2M Form 4	Filing · EDGAR
Jazz Pharmaceuticals JAZZ · Morgan Stanley Smith Barney · 10b5-1 plan adopted Dec 6, 2024 · 2 notices
Nov 17, 2025	7,159 · ~$1.2M	Nov 17, 2025	Sold as noticed Sold 7,159 at $168.26 on Nov 17 · $1.2M Form 4	Filing · EDGAR
Mar 7, 2025	5,466 · ~$758K	Mar 7, 2025	Partly sold Sold 3,951 in 2 sales, Mar 7 to Mar 10 · $549K likely match Form 4 (1) · Form 4 (2)	Filing · EDGAR
Jazz Pharmaceuticals JAZZ · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 2 notices
Mar 10, 2025	1,767 · ~$256K	Mar 10, 2025	Not sold within 90 days	Filing · EDGAR
Mar 7, 2025	4,017 · ~$571K	Mar 7, 2025	Not sold within 90 days	Filing · EDGAR
Sales without a matching Form 144 · 2 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice Jazz Pharmaceuticals (JAZZ): Sold 5,532 at $138.21 on Mar 7, 2025 · $765K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Jazz Pharmaceuticals (JAZZ): Sold 1,844 at $151.54 on Dec 9, 2022 · $279K	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Jazz Pharmaceuticals JAZZ EVP, Global Head of R&D & CMO · filings 2019 to 2026 · sold $22M · $22M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 27, 2026	Option or RSU exercised or converted	+26,116	$113.10	$3M	111,223 direct	Filing · EDGAR
Aug 27, 2026	Option or RSU exercised or converted	+884	$113.10	$100K	112,107 direct	Filing · EDGAR
Aug 27, 2026	Option or RSU exercised or converted	+27,584	$137.12	$3.8M	139,691 direct	Filing · EDGAR
Aug 27, 2026	Option or RSU exercised or converted	+2,916	$137.12	$400K	142,607 direct	Filing · EDGAR
Aug 27, 2026	Sale under a 10b5-1 plan	−18,187	$247.86	$4.5M	124,420 direct	Filing · EDGAR
Aug 27, 2026	Sale under a 10b5-1 plan	−11,423	$248.67	$2.8M	112,997 direct	Filing · EDGAR
Aug 27, 2026	Sale under a 10b5-1 plan	−18,113	$250.02	$4.5M	94,884 direct	Filing · EDGAR
Aug 27, 2026	Sale under a 10b5-1 plan	−19,639	$250.60	$4.9M	75,245 direct	Filing · EDGAR
Aug 27, 2026	Sale under a 10b5-1 plan	−9,259	$251.95	$2.3M	65,986 direct	Filing · EDGAR
Aug 27, 2026	Sale under a 10b5-1 plan	−300	$252.76	$76K	65,686 direct	Filing · EDGAR
Aug 27, 2026	Option or RSU exercised or converted Incentive Stock Option (right to buy)	−884			0 direct	Filing · EDGAR
Aug 27, 2026	Option or RSU exercised or converted Incentive Stock Option (right to buy)	−2,916			0 direct	Filing · EDGAR
Aug 27, 2026	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−26,116			0 direct	Filing · EDGAR
Aug 27, 2026	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−27,584			0 direct	Filing · EDGAR
Jun 30, 2026	Shares withheld for tax or exercise price	−3,764	$237.72	$895K	85,107 direct	Filing · EDGAR
Mar 5, 2026	Shares withheld for tax or exercise price	−6,209	$188.69	$1.2M	88,871 direct	Filing · EDGAR
Feb 26, 2026	Grant or award from the company	+14,822			95,080 direct	Filing · EDGAR
Jan 16, 2026	Grant or award from the company	+11,699			84,398 direct	Filing · EDGAR
Jan 16, 2026	Shares withheld for tax or exercise price	−4,140	$171.16	$709K	80,258 direct	Filing · EDGAR
Nov 17, 2025	Sale under a 10b5-1 plan	−7,159	$168.26	$1.2M	72,628 direct	Filing · EDGAR
Mar 10, 2025	Open-market or private sale	−2,403	$138.41	$333K	79,621 direct	Filing · EDGAR
Mar 7, 2025	Sale under a 10b5-1 plan	−5,532	$138.21	$765K	83,572 direct	Filing · EDGAR
Mar 7, 2025	Sale under a 10b5-1 plan	−1,548	$140.00	$217K	82,024 direct	Filing · EDGAR
Mar 5, 2025	Returned to the company	−5,239	$138.95	$728K	89,104 direct	Filing · EDGAR
Feb 27, 2025	Grant or award from the company	+17,718			85,484 direct	Filing · EDGAR
Feb 27, 2025	Grant or award from the company	+8,859			94,343 direct	Filing · EDGAR
Jan 17, 2025	Grant or award from the company	+7,506			69,947 direct	Filing · EDGAR
Jan 17, 2025	Shares withheld for tax or exercise price	−2,181	$122.62	$267K	67,766 direct	Filing · EDGAR
Mar 5, 2024	Shares withheld for tax or exercise price	−4,294	$117.53	$505K	62,226 direct	Filing · EDGAR
Mar 1, 2024	Grant or award from the company	+16,928			66,520 direct	Filing · EDGAR
Jan 17, 2024	Grant or award from the company	+5,970			51,322 direct	Filing · EDGAR
Jan 17, 2024	Shares withheld for tax or exercise price	−1,730	$119.13	$206K	49,592 direct	Filing · EDGAR
Jun 5, 2023	Returned to the company	−1,311	$129.73	$170K	45,315 direct	Filing · EDGAR
Mar 5, 2023	Shares withheld for tax or exercise price	−2,274	$142.78	$325K	46,489 direct	Filing · EDGAR
Mar 3, 2023	Grant or award from the company	+12,447			48,763 direct	Filing · EDGAR
Dec 9, 2022	Open-market or private sale	−1,844	$151.54	$279K	36,316 direct	Filing · EDGAR
Jun 6, 2022	Shares withheld for tax or exercise price	−1,295	$149.25	$193K	38,109 direct	Filing · EDGAR
Mar 5, 2022	Shares withheld for tax or exercise price	−1,327	$153.96	$204K	39,257 direct	Filing · EDGAR
Mar 3, 2022	Grant or award from the company	+11,374			40,584 direct	Filing · EDGAR
Jun 5, 2021	Shares withheld for tax or exercise price	−1,206	$176.47	$213K	29,086 direct	Filing · EDGAR
Mar 5, 2021	Shares withheld for tax or exercise price	−741	$164.75	$122K	30,145 direct	Filing · EDGAR
Feb 25, 2021	Grant or award from the company	+8,535			30,886 direct	Filing · EDGAR
Jun 5, 2020	Shares withheld for tax or exercise price	−943	$120.65	$114K	22,204 direct	Filing · EDGAR
Feb 27, 2020	Grant or award from the company	+10,800			23,000 direct	Filing · EDGAR
Feb 27, 2020	Grant or award from the company Incentive Stock Option (right to buy)	+884			884 direct	Filing · EDGAR
Feb 27, 2020	Grant or award from the company Non-Qualified Stock Option (right to buy)	+26,116			26,116 direct	Filing · EDGAR
Aug 8, 2019	Grant or award from the company	+12,200			12,200 direct	Filing · EDGAR
Aug 8, 2019	Grant or award from the company Incentive Stock Option (right to buy)	+2,916			2,916 direct	Filing · EDGAR
Aug 8, 2019	Grant or award from the company Non-Qualified Stock Option (right to buy)	+27,584			27,584 direct	Filing · EDGAR

Pliant Therapeutics PLRX Director · filings 2026 to 2026

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 9, 2026	Grant or award from the company Stock Option (Right to Buy)	+60,000			60,000 direct	Filing · EDGAR

Autolus Therapeutics AUTL Director · filings 2026 to 2026

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 29, 2026	Grant or award from the company Restricted Share Units	+31,667			31,667 direct	Filing · EDGAR
Jun 29, 2026	Grant or award from the company Share Option (Right to Buy)	+47,500			47,500 direct	Filing · EDGAR

iTeos Therapeutics Director · filings 2021 to 2024

Date	Transaction	Shares	Held after	Source
Jun 11, 2024	Grant or award from the company Stock Option (Right to Buy)	+24,200	24,200 direct	Filing · EDGAR
Jun 13, 2023	Grant or award from the company Stock Option (Right to Buy)	+22,383	22,383 direct	Filing · EDGAR
Jun 9, 2022	Grant or award from the company Stock Option (Right to Buy)	+17,538	17,538 direct	Filing · EDGAR
Jun 17, 2021	Grant or award from the company Stock Option (Right to Buy)	+4,560	4,560 direct	Filing · EDGAR
Apr 29, 2021	Grant or award from the company Stock Option (Right to Buy)	+33,217	0 direct	Filing · EDGAR

Jounce Therapeutics Director · filings 2020 to 2023

Date	Transaction	Shares	Held after	Source
May 3, 2023	Returned to the company Stock Option (Right to Buy)	−31,400	0 direct	Filing · EDGAR
May 3, 2023	Returned to the company Stock Option (Right to Buy)	−7,850	0 direct	Filing · EDGAR
May 3, 2023	Returned to the company Stock Option (Right to Buy)	−15,700	0 direct	Filing · EDGAR
May 3, 2023	Returned to the company Stock Option (Right to Buy)	−20,000	0 direct	Filing · EDGAR
Jun 24, 2022	Grant or award from the company Stock Option (Right to Buy)	+20,000	20,000 direct	Filing · EDGAR
Jun 18, 2021	Grant or award from the company Stock Option (Right to Buy)	+15,700	15,700 direct	Filing · EDGAR
Jun 26, 2020	Grant or award from the company Stock Option (Right to Buy)	+7,850	7,850 direct	Filing · EDGAR
Jan 21, 2020	Grant or award from the company Stock Option (Right to Buy)	+31,400	31,400 direct	Filing · EDGAR

Immunomedics Chief medical officer · filings 2018 to 2019

Date	Transaction	Shares	Held after	Source
Mar 14, 2019	Grant or award from the company Stock Option (right to buy)	+51,230	51,230 direct	Filing · EDGAR
Mar 14, 2019	Grant or award from the company Stock Option (right to buy)	+25,660	25,660 direct	Filing · EDGAR
Sep 14, 2018	Grant or award from the company Stock Options (right to buy)	+15,900	15,900 direct	Filing · EDGAR

All 50 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Aug 31, 2026	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Aug 27, 2026	Form 144	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jul 13, 2026	Form 3	Pliant Therapeutics PLRX	Filing · EDGAR
Jul 13, 2026	Form 4	Pliant Therapeutics PLRX	Filing · EDGAR
Jul 2, 2026	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jul 1, 2026	Form 4	Autolus Therapeutics AUTL	Filing · EDGAR
Mar 18, 2026	Form 3	Autolus Therapeutics AUTL	Filing · EDGAR
Mar 9, 2026	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Mar 2, 2026	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jan 21, 2026	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Nov 19, 2025	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Nov 17, 2025	Form 144	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Mar 12, 2025	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Mar 10, 2025	Form 144	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Mar 7, 2025	Form 144	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Mar 7, 2025	Form 144	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Mar 7, 2025	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Mar 3, 2025	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jan 22, 2025	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jun 13, 2024	Form 4	iTeos Therapeutics	Filing · EDGAR
Mar 7, 2024	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Mar 5, 2024	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jan 19, 2024	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jun 15, 2023	Form 4	iTeos Therapeutics	Filing · EDGAR
Jun 7, 2023	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
May 4, 2023	Form 4	Jounce Therapeutics	Filing · EDGAR
Mar 7, 2023	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Dec 13, 2022	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jun 28, 2022	Form 4	Jounce Therapeutics	Filing · EDGAR
Jun 10, 2022	Form 4	iTeos Therapeutics	Filing · EDGAR
Jun 8, 2022	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Mar 9, 2022	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jun 22, 2021	Form 4	Jounce Therapeutics	Filing · EDGAR
Jun 21, 2021	Form 4	iTeos Therapeutics	Filing · EDGAR
Jun 9, 2021	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
May 3, 2021	Form 4	iTeos Therapeutics	Filing · EDGAR
May 3, 2021	Form 3	iTeos Therapeutics	Filing · EDGAR
Mar 9, 2021	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Mar 1, 2021	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jul 2, 2020	Form 4/A	Jounce Therapeutics	Filing · EDGAR
Jun 29, 2020	Form 4	Jounce Therapeutics	Filing · EDGAR
Jun 5, 2020	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Mar 2, 2020	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jan 23, 2020	Form 4	Jounce Therapeutics	Filing · EDGAR
Jan 23, 2020	Form 3	Jounce Therapeutics	Filing · EDGAR
Aug 12, 2019	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jun 4, 2019	Form 3	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Mar 18, 2019	Form 4	Immunomedics	Filing · EDGAR
Sep 18, 2018	Form 4	Immunomedics	Filing · EDGAR
Apr 23, 2018	Form 3	Immunomedics	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 1:00 AM ET. The filing on SEC.gov is the record.